KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Equity Ratio (2016 - 2025)

Nektar Therapeutics has reported Equity Ratio over the past 16 years, most recently at 0.32 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.32 for Q4 2025, up 60.27% from a year ago — trailing twelve months through Dec 2025 was 0.32 (up 60.27% YoY), and the annual figure for FY2025 was 0.32, up 60.27%.
  • Equity Ratio for Q4 2025 was 0.32 at Nektar Therapeutics, up from 0.28 in the prior quarter.
  • Over the last five years, Equity Ratio for NKTR hit a ceiling of 0.68 in Q1 2021 and a floor of 0.12 in Q2 2025.
  • Median Equity Ratio over the past 5 years was 0.38 (2023), compared with a mean of 0.39.
  • Peak annual rise in Equity Ratio hit 77.88% in 2025, while the deepest fall reached 150.26% in 2025.
  • Nektar Therapeutics' Equity Ratio stood at 0.61 in 2021, then fell by 15.17% to 0.52 in 2022, then plummeted by 36.22% to 0.33 in 2023, then plummeted by 39.26% to 0.2 in 2024, then surged by 60.27% to 0.32 in 2025.
  • The last three reported values for Equity Ratio were 0.32 (Q4 2025), 0.28 (Q3 2025), and 0.12 (Q2 2025) per Business Quant data.